Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations-Reference-Cited by-同舟云学术

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations

Published:2024-05-17 Issue:8 Volume:99 Page:1620-1623
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Langerbeins Petra¹^ORCID,Giza Adam¹,Robrecht Sandra¹,Cramer Paula¹^ORCID,von Tresckow Julia²,Al‐Sawaf Othman¹^ORCID,Fink Anna Maria¹,Fürstenau Moritz¹^ORCID,Kater Arnon P.³,van der Spek Ellen⁴,Niemann Carsten Utoft⁵,da Cunha‐Bang Caspar⁵,Tausch Eugen⁶,Schneider Christof⁶,Stilgenbauer Stephan⁶,Fischer Kirsten¹,Hallek Michael¹,Eichhorst Barbara¹

Affiliation:

1. Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) University of Cologne, Faculty of Medicine and University Hospital Cologne Cologne Germany

2. Department of Hematology and Stem Cell Transplantation, West German Cancer Center University of Duisburg‐Essen Essen Germany

3. Department of Hematology, Cancer Center Amsterdam Amsterdam University Medical Centers, University of Amsterdam Amsterdam Netherlands

4. Department of Internal Medicine Rijnstate Hospital Arnhem Netherlands

5. Department of Hematology Rigshospitalet Copenhagen Denmark

6. Department of Internal Medicine III, Division of CLL University Hospital Ulm Ulm Germany

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27367

Reference6 articles.

1. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia

2. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

3. Immune failure, infection and survival in chronic lymphocytic leukemia

4. Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

5. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study